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The Centre/or Bioethics and Patient Advocacy has heen taking part in the Ellropean ForuIn 
for Good Clinical Practice (EFGCP) 'sformulation olguidelinesfor implementing Directive 
200 11201EC' relating to good clinical practice in the conduct olclinical trials on human 
su~iects. The documen! produced by this group fa cl/sed on clinical trials in children and 
their protection thereof As clinical trials become nwre important and common, a harmonization 
of the application of this directive across Europe was deemed important. 
"Children are not small adults and 
there is a need to carry out specific 
trials that cannot be performed in 
adults."2 Ethics committees need 
paediatric expertise as the lack of 
competence of children to give 
informed consent renders this group a 
vulnerable population. In particular 
parents are prone to accept their 
children participating in a trial upon 
the suggestion of the health care team. 
The lack of legal ability to consent has 
therefore also implications on the 
design, analysis and the choice of 
comparators used in trials. There is a 
need for clinical trials in children, 
especially because many drugs given 
to them are off-label. Moreover trials 
may be specific to this population, 
such as vaccinations. 
The Declaration of Helsinki states 
that, "When a subject deemed legally 
incompetent, such as a minor child, is 
able to give assent to decision about 
participation in research, the 
investigator must obtain that assent in 
addition to the consent of the legally 
authorized representative. "3 This 
implies that enough information must 
be given to the child by an experienced 
professional, which the child is able 
to assimilate and understand. Article 
4 of the Clinical Trials Directive 
stipulates therefore "the explicit wish 
of a minor who is capable of forming 
an opinion and assessing this 
information to refuse participation or 
to be withdrawn from the clinical trial 
at any time is considered by the 
investigator or where appropriate the 
principle investigator. "2 
As the child however is only capable 
of giving assent and not informed 
consent, one still needs to follow the 
five conditions4.5 to obtain valid 
consent from the legal representative 
of the child. Sufficient time to consider 
the risks and benefits should be 
allowed for. 2 The document divides 
children into three age groups. Those 
under three years of age cannot give 
realistic assent whilst those over three 
are thought to understand some form 
of altruism. As the child gets older, 
children may be able to understand 
and evaluate the risks and benefits of 
the research, and their expression must 
therefore be taken into account. The 
third group, adolescents, proves most 
difficult. Sometimes there can be 
situations in which confidentiality is 
at stake - some EU states advice 
discretion and professional secrecy 
vis-sa-vis parents when dealing with 
this group. Obtaining consent from 
parents becomes difficult, if legally 
required, when assent is available fonn 
the adolescent, who is technically still 
considered a child under the legal 
guardianship of the parents. 
Conversely, "when the child is legally 
emancipated, i.e. ceases to be a minor, 
infonned consent must be sought 
directly from the individual and as 
soon as possible".2 
The Clinical Trials Directive requires 
the need for ethics committees to have 
paediatric expertise to give advice in 
the clinical, ethical and psychosocial 
problems in the field of paediatrics, 
which differ of course from the usual 
clinical trials in adults. This may be a 
paediatrician experienced in paediatric 
research and trials, but also a paediatric 
pharmacologist, paediatric nurse, 
paediatric ethicist or psychologist. If 
the ethics committee is not in charge 
of scientific review according to 
national law, it should make sure that 
adequate peer review by experts in the 
field has taken place - for example 
that thc trial us cs agc-appropriatc 
formulations of the medicinal product, 
or that appropriate amounts of blood 
are drawn, where this is necessary, 
considering that the volume of blood 
to be drawn is over and above that for 
the normal hospital stay. An amount 
not more that 1.2 ml has been 
suggested for children under three, 
especially babies. 
Equipoise is important when 
considering a control group or the use 
of a placebo. The physician must be 
morally certain that the child is not 
better off not participating in the trial. 
Equipoise may be waived however 
when the trial does not involve control 
groups, for example post-marketing 
surveillance studies. It has also been 
suggested that research on certain 
drugs, following of course the scientific 
advice given by the professionals 
mentioned, should be offered only on 
premises where appropriate "rescue 
treatment and escape procedures" are 
available, should a serious harm occur.2 
Of course an obvious requirement is 
that physical and emotional pain 
should be prevented as much as 
possible. To do this however requires 
appropriate monitoring on a regular 
basis according to guidelines and 
validated scales, particularly in pre-
term, newborn and other children who 
cannot express themselves. Effective 
treatment in relation to the intensity 
of pain should be administered and 
reviewed regularly. Repeated blood 
sampling and the insertion of 
indwelling catheters are all sources of 
pain, and available pharmacokinetic 
data from population studies may 
reduce the number of samples in each 
child. 
Risk assessment is crucial when 
assessing trials. In children particularly, 
besides the physical risks, one must 
consider the psychological or social 
risks, which may be immediate or 
delayed and which may vary according 
to age. Absenteeism from school may 
be a small issue to the health care team, 
but may have a large impact over a 
stretched period of time. It is often the 
case that the research is spread over 
the availability of the research team 
and not ofthe child's timetable. Ethics 
committees may intervene when it is 
deemed that the particular age group 
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may be adversety affected, and that 
appropnate arrangements, such as the 
use of holidays, are used to bring 
children to the facilities , unless one is 
dealing with hospitalised children. It 
is all too easy to instruct parents that 
they must then continue to bring in 
the child once a week (when this may 
not have been adequately expressed 
in the infonned consent process). 
Parents are usually the first to express 
concern about how much time is lost 
from school. 
However the risk-benefit analysis 
may evolve over time, especially where 
the safety of the drug is concerned, 
and this must be continuous evaluated, 
with the provision of being able to 
stop the study if necessary. There are 
various protocols and tables of 
assessing what are minimal risks, and 
which are major ones. These must be 
presented by the trial sponsors and 
need to be evaluated by the Ethics 
Committee, which usually tries to 
ascertain that risks are minimal as well 
as the burden, and that the research 
has the aim of providing significant 
improvements in the scientific 
understanding of the condition or 
disease, which are able to provide 
benefit to the participant of the trial 
and other persons of the same age 
category. 
More tricky are phase one trials, 
in which healthy volunteers are 
used. Healthy children must be used 
III order to understand the 
pharmacokinetics and 
pharmacodynamics of a drug, 
without the interference of the 
disease process. Phase one involves 
small numbers , usually in the order 
of tens; but still, assessing and 
imparting information of risk may 
be more difficult, unless one 
produces prior evidence of adult 
studies, or at least animal studies. 
This may not be necessary where 
the aim is to find age-appropriate 
dosages or for trials for vaccines. 
Whenever possible, it is suggested 
that older children should be 
considered for inclusion before 
younger ones, although the 
document2 does not give particular 
reasons for this, other than the 
impression that the younger the 
child, the more vulnerable they are, 
and probably the more prone to 
risks. This may reduce the impact 
on future tests on younger children. 
Finally the directive admonishes 
researchers performing research in 
non-EU countries, to strictly follow 
the same guidelines and GCP standards 
that are required within the EU. Indeed 
this is not only about patient rights, 
but at the end of the day, also about 
the scientific validity of the trial, for 
research which is not up to Good 
Clinical Practice standards has been 
found not to be scientifically valid . 8.J 
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Only paragraph 188 has a title, though all of the paragraphs 
include the phrase: "if you examine a man with a ... " a 
characteristic which denotes its similarity to the Edwin Smith 
Papyrus. From this point, a declaration of the diagnosis, but 
no prognosis can be found. After paragraph 207, the text reverts 
to its original style, with a short treatise on the heart (Paragraphs 
208-241). Paragraphs 242-247 contain remedies which are 
reputed to have been made and used personally by various 
gods. Only in paragraph 247, contained within the above 
mentioned section and relating to Isis' creation of a remedy 
for an illness in Ra's head, is a specific diagnosis mentioned. 
The following section continues with diseases of the head, but 
without reference to the use of remedies by the gods. Paragraph 
250 contains a famous passage concerning the treatment of 
migraines. The sequence is interrupted in paragraph 25 1 with 
the focus placed on a drug rather than an illness. Most likely 
an extract from phannacopoeia, the paragraph begins: 
"Knowledge of what is made Fom degem (most likely a ricinous 
plant yielding a/arm of castor oil), as somethingfound in 
ancient writings and as something useful to man." Paragraphs 
261 -283 are concerned with the regular flow of urine and are 
followed by remedies "to cause the heart to receive bread." 
Paragraphs 305-335 contain remedies for various fonns of 
coughs as well as the genew disease. The remainder of the text 
goes on to discuss medical conditions concerning hair 
(paragraphs 437-476), traumatic injuries such as bums and 
flesh wounds (paragraphs 482-529), and diseases of the 
extremities such as toes, fmgers and legs. Paragraphs 627-696 
are concerned with the relaxation or strengthening of the metu. 
The exact meaning of metu is confusing and could be 
alternatively translated as either meaning hollow vessels or 
muscles tissue. The papyrus continues by featuring diseases 
of the tongue (paragraphs 697-704), dennatological conditions 
(paragraphs 708-721), dental conditions (paragraphs 739-750), 
diseases of the ear, nose, and throat (paragraphs 761 -781), and 
gynecological conditions (paragraphs 783-839). 8.J 
